This study evaluates the safety and clinical activity of telaglenastat (CB-839), a glutamase inhibitor, with pembrolizumab and chemotherapy, for first line treatment of metastatic NSCLC with NF1, KEAP1/NRF2, or LKB1 mutations. This evidence concerns the gene NF1 and non-small cell lung carcinoma.